Effect of Timed-Restricted Eating on Metabolic Health (TREAT)

The Effect of Timed-Restricted Eating on Insulin Sensitivity, De Novo Lipogenesis and Liver Fat in Subjects With Obesity and Insulin Resistance

We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin resistance.

Study Overview

• Status: Recruiting
• Conditions: Obesity; Insulin Resistance; Non-Alcoholic Fatty Liver Disease
• Intervention / Treatment: Behavioral: Early time restricted eating; Behavioral: Late time restricted eating

Detailed Description

Obesity is an alarming global health issue, with increasing prevalence. Obesity leads to a vast array of disorders, including dyslipidemia, the accumulation of intrahepatic triglycerides (IHTG), multiorgan insulin resistance and type 2 diabetes mellitus. In addition, disruption of the circadian rhythm (circadian misalignment), which is associated with irregular eating schedules, is an important risk factor for the development of obesity, IHTG and type 2 diabetes mellitus. Time restricted eating (TRE) is a form of intermittent fasting, in which the daily eating period is restricted. The beneficial effect of this type of diet might relate to adequate synchronization of food intake and fasting to the internal rhythm of the circadian tissue clocks, improving metabolic handling of nutrients and metabolic flexibility.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jur Kroon, BSc; Phone Number: +31 683238752; Email: jur.kroon@amsterdamumc.nl
• Study Contact Backup: Name: Sarah E Siegelaar, MD PhD; Email: s.e.siegelaar@amsterdamumc.nl

Study Locations

• Netherlands
  • Noord-Holland
    • Amsterdam, Noord-Holland, Netherlands, 1105AZ
      • Recruiting
      • Amsterdam UMC, location AMC
      • Contact: Jur Kroon, BSc; Phone Number: +31 683238752; Email: jur.kroon@amsterdamumc.nl
      • Sub-Investigator: Jur Kroon, BSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Ability to provide informed consent;
• BMI > 30kg/m^2;
• Insulin resistance, as defined by fasting plasma insulin > 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose > 5.3 and < 7.0 mmol/L;
• Stable weight for 3 months prior to study inclusion
• For women, 1 year after last menstrual cycle

Exclusion Criteria:

• Use of any medication, except for those related to treatment of metabolic syndrome;
• Any medical condition interfering with study outcomes or design;
• History of any psychiatric disorder, including eating disorders;
• Performing shift work
• Performing intensive sports (>3 hours/week);
• Smoking;
• Drugs abuse or alcohol abuse (>3 units/day);
• Contraindication for MRI;
• Known lactose/gluten intolerance;
• Known soy, egg, milk or peanut allergy;
• Childhood onset of obesity

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Early time-restricted eating; 50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM.; Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM.	Behavioral: Early time restricted eating; Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM; Other Names: early-TRE
Experimental: Late time-restricted eating; 15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM.; Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM.	Behavioral: Late time restricted eating; Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM; Other Names: late-TRE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Insulin Sensitivity	We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in plasma insulin	Fasted and stimulated insulin (pmol/L) will be measured during MMTT	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in plasma glucose	Fasted and stimulated glucose (mmol/L) will be measured during MMTT	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in intrahepatic fat	To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in beta cell function (C-peptide)	Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in insulin aignaling	Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in glucose variability	In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.	Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
De novo lipogenesis	Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Immunological markers	We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Physical activity	Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.	Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
Functional brain activity	Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Food Craving	We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Eating behaviour	We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Hunger scale	We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Food addiction	We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Impulsiveness	We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Chronotype	To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Subject experience with intervention	We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Delay discounting computational task	The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Iowa gambling computational task	We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.	Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Collaborators and Investigators

• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Collaborators: Diabetesfonds
• Investigators: Principal Investigator: Mireille JM Serlie, MD PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2023
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: September 24, 2023
• First Submitted That Met QC Criteria: September 24, 2023
• First Posted (Actual): September 29, 2023

Study Record Updates

• Last Update Posted (Actual): September 29, 2023
• Last Update Submitted That Met QC Criteria: September 24, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Hyperinsulinism; Liver Diseases; Obesity; Fatty Liver; Insulin Resistance; Non-alcoholic Fatty Liver Disease
• Other Study ID Numbers: NL79197.018.21

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No